Trials / Unknown
UnknownNCT04727008
CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma
Phase I Study of A CXCR4 Modified BCMA CAR-T in Patients With Refractory and/or Relapsed Multiple Myeloma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Sichuan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Multiple myeloma (MM) is an incurable plasma cell cancer that almost all patients eventually relapse despite advancement in treatment strategies. B-cell maturation antigen (BCMA) is a cell surface receptor that expressed primarily by malignant and normal plasma cells. This study aims to evaluate the safety and tolerance CXCR4 modified BCMA CAR T cells in treating standard treatment failed refractory/relapsed multiple myeloma, and will follow dose-escalating cohorts. The efficacy of CXCR4 modified BCMA CAR T will also be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CXCR4 modified anti-BCMA CAR T cells | intravenous infusion |
Timeline
- Start date
- 2022-09-21
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2021-01-27
- Last updated
- 2023-12-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04727008. Inclusion in this directory is not an endorsement.